Coagulation factor XI, His, Human
Coagulation Factor XI, His, Human

Immobilized Coagulation factor XI, His, Human, His Tag at 1 μg /ml (100 μl/well) on the plate. Dose response curve for Anti-factor XI Antibody, hFc Tag with the EC50 of 3.7ng/ml determined by ELISA.

Coagulation Factor XI, His, Human

The purity of Coagulation factor XI, His, Human is greater than 95% as determined by SEC-HPLC.

Coagulation Factor XI, His, Human

Coagulation factor XI, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Coagulation factor XI, His, Human

Coagulation factor (F)XI has been described as a component of the early phase of the contact pathway of blood coagulation, acting downstream of factor XII.In contrast to its mild hemostatic activities, FXI is known to play a significant role in thrombosis, as it is a demonstrated independent risk factor for deep vein thrombosis, ischemic stroke, and myocardial infarction. A better understanding of the varied and complex role of FXI in both thrombosis and hemostasis will help to allow better prediction of bleeding risk in FXI-deficient patients and also informing the development of targeted agents to inhibit the thrombotic activities of FXI while preserving hemostasis.
Z05185
¥80,213.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Coagulation factor XI (Glu19-Val625)
Accession # P03951-1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.Measured by its binding ability in a functional ELISA. Measured by its ability to cleave the fluorogenic peptide substrate, t­butyloxycarbonyl­Ile­Glu­ Gly­Arg­7­amido­4­methylcoumarin (Boc­IEGR­AMC). Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 69.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in 25mM HEPES, 150mM NaCl (pH 7.5).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • Coagulation Factor XI, His, Human
    • Coagulation Factor XI, His, Human

    Immobilized Coagulation factor XI, His, Human, His Tag at 1 μg /ml (100 μl/well) on the plate. Dose response curve for Anti-factor XI Antibody, hFc Tag with the EC50 of 3.7ng/ml determined by ELISA.

  • Coagulation Factor XI, His, Human
    • Coagulation Factor XI, His, Human

    The purity of Coagulation factor XI, His, Human is greater than 95% as determined by SEC-HPLC.

  • Coagulation Factor XI, His, Human
    • Coagulation Factor XI, His, Human

    Coagulation factor XI, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Coagulation factor (F)XI has been described as a component of the early phase of the contact pathway of blood coagulation, acting downstream of factor XII.In contrast to its mild hemostatic activities, FXI is known to play a significant role in thrombosis, as it is a demonstrated independent risk factor for deep vein thrombosis, ischemic stroke, and myocardial infarction. A better understanding of the varied and complex role of FXI in both thrombosis and hemostasis will help to allow better prediction of bleeding risk in FXI-deficient patients and also informing the development of targeted agents to inhibit the thrombotic activities of FXI while preserving hemostasis.
Synonyms Coagulation factor XI; FXI; PTA; F11;

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.